This Acquirers Multiple Stock Is Undervalued, According to Dalio, Simons, Griffin

Part of the weekly research here at The Acquirer’s Multiple features some of the top picks from our Stock Screeners and some top investors who are holding these same picks in their portfolios. Investors such as Warren Buffett, Joel Greenblatt, Carl Icahn, Jim Simons, Prem Watsa, Jeremy Grantham, Seth Klarman, Ray Dalio, and Howard Marks. The top investor data is provided from their latest 13F’s. This week we’ll take a look at:

GSK PLC (GSK)

In the pharmaceutical industry, GSK ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

A quick look at the price chart below shows us that the stock is up 5.26% in the past twelve months. We currently have the stock trading on an Acquirer’s Multiple of 10.80 which means that it remains undervalued.

GSK data by YCharts

(Shares)

Ken Fisher – 13,600,393

Jim Simons – 2,911,993

Israel Englander – 2,624,131

Ken Griffin – 532,610

Ray Dalio – 178,038

John Rogers – 141,497

Louis Bacon – 87,087

Murray Stahl – 24,938